CEO Clinics are an intimate forum for confidential exchange on a given topic and therefore limited to 5 - 6 Members. 

If you are interested in joining this Clinic, please RSVP. In the event that more than 5 people sign up, we will allocate places one week before the event.

Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industries, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.

He holds a doctorate in economics from Vienna University, earned his Master's degrees from Harvard University, and holds a degree in Psychology. Dr Werner Lanthaler serves in the Boards of Directors of AC Immune SA (since July 2018) and arGEN-X SE (since April 2014), where he also serves as Chairman of the Audit Committee. He is also member of the Supervisory Board of Topas Therapeutics GmbH (since October 2015).